Table 2.
No. | Age/Sex | Site (s) of involvement | Symptom (s) and its duration | Basic morphology | CD3 | CD5 | CD7 | CD4 | CD8 | βF1 | CD56 | TIA1 | GB | PF | CD45 | CD30 | EBER | TCR gene | Clinical course |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 74/M | Nasal cavity | Rhinorrhea, 1 year | large (A+, N+) | + | - | - | - | - | - | + | + | + | + | + | + | + | I | D, 3 mos |
2 | 40/M | Nasal cavity | Nasal obstruction, 3 mos | medium (A+, N+) | p+ | - | - | - | - | - | - | + | p+ | p+ | - | + | + | I | D, 33 mos |
3 | 31/M | Nasal cavity | Nasal obstruction, 1 mo | large (A+, N+) | p+ | - | - | - | - | - | + | + | + | + | + | + | + | - | D, 37 mos |
4 | 37/M | Nasal cavity | Orbital cellulitis, and fever, 2 mos | medium (A-, N+) | p+ | - | - | - | - | - | p- | + | p+ | + | NA | + | + | - | D, 3 mos |
5 | 41/F | Nasal cavity | Nasal obstruction, 1 mo | small to medium (A+, N+) | + | - | NA | - | - | - | + | + | p+ | + | + | NA | + | - | D, 3 mos |
6 | 49/F | Nasal cavity | Nasal obstruction, 2 mos | medium to large (A-, N+) | + | - | + | - | - | - | + | + | + | + | + | p+ | + | - | A, 60 mos |
7 | 43/F | Nasal cavity | Nasal obstruction, 2 mos | medium to large (A+, N+) | p+ | - | - | p+ | - | - | + | + | + | + | - | p+ | + | - | D, 8 mos |
8 | 32/M | Nasal cavity | Nasal obstruction, 5 mos | medium to large (A-, N+) | + | - | p- | - | - | - | + | + | p+ | p+ | NA | - | + | - | D, 3 mos |
9 | 33/M | Nasal cavity | Rhinorrhea, 1 mo | medium (A+, N+) | + | - | + | - | - | - | + | + | p- | p- | p+ | + | + | - | D, 4 mos |
10 | 38/M | Nasal cavity | Nasal obstruction with epistaxis, 2 yrs | medium (A+, N+) | + | - | - | - | - | - | p+ | + | + | + | + | + | + | I | D, 7 mos |
11 | 48/F | Nasal and oral cavities | Nasal obstruction, 1 mos | medium to large (A+, N+) | + | p+ | NA | - | - | - | p+ | + | p+ | p+ | NA | - | + | - | D, 3 mos |
12 | 36/M | Nasal cavity and nasopharynx | Epistaxis with fever, 1 mo | small to medium (A+, N+) | + | - | + | - | - | - | + | + | p+ | p- | p+ | - | + | - | D, 1 mos |
13 | 26/F | Nasal cavity and nasopharynx | Rhinorrhea, 2 mos | medium (A+, N+) | + | p+ | + | - | - | - | + | + | + | + | NA | - | + | - | D, 4 mos |
14 | 42/M | Nasal cavity and nasopharynx | Epistaxis (HIV+), 2 mos | medium to large (A-, N+) | + | - | - | p+ | - | - | + | + | + | + | p+ | p+ | + | - | D, 18 mos |
15 | 41/M | Nasopharynx | Dysphagia, 3 mos | medium (A+, N-) | + | - | - | - | - | - | p+ | + | + | + | + | + | + | - | D, 11 mos |
16 | 44/M | Nasopharynx | Rhinorrhea with epistaxis, 6 mos | medium to large (A+, N+) | - | - | - | - | - | - | - | + | p+ | - | - | + | + | - | D, 2 mos |
17 | 42/M | Nasopharynx | Nasal obstruction, 1 wk | medium to large (A+, N+) | + | - | + | - | - | - | + | + | + | + | p+ | + | + | I | D, 5 mos |
18 | 57/F | Oral cavity | Palatal mass, 2 mos | large (A+, N+) | + | - | - | - | - | - | + | + | + | + | p+ | - | + | - | D, 4 mos |
19 | 38/M | Oral cavity | Chronic oral ulcer, 3 mos | medium to large (A-, N+) | + | - | - | - | - | - | - | + | + | p+ | + | p+ | + | - | D, 3 mos |
20 | 73/M | Base of tongue and larynx | Dysphagia, 2 mos | medium to large (A+, N+) | p+ | - | NA | - | - | - | + | + | + | + | p+ | NA | + | - | D, 6 mos |
21 | 66/M | Periorbital soft tissue | Orbital cellulitis, 2 wks | medium to large (A+, N+) | - | - | p+ | - | - | - | + | + | + | + | p+ | + | + | - | D, 3 mos |
22 | 56/M | Periorbital soft tissue | Blurred vision and headache, 2 mos | medium to large (A+, N+) | + | - | - | p+ | - | - | + | + | p+ | p+ | + | p+ | + | - | D, 10 mos |
* Please see the abbreviations below
For "basic morphology": Large: predominantly (>75%) large cells; Medium to large: mixture of medium-sized to large cells (≥25% each); Medium: predominantly (>75%) medium-sized cells; Small to medium: mixture of small to medium-sized cells (≥25% each); A+: presence of angioinvasion; A-: absence of angioinvasion; N+: presence of tissue necrosis; N-: absence of tissue necrosis
For immunophenotype: GB: granzyme B; PF: perforin; + (mostly positive): positive on lymphoma cells >50%; p+ (partially positive): 10-50% positive; p- (probably negative): <10% staining; - (negative): clearly negative; NA: not available
For TCR gene (PCR -based TCR gene rearrangement analysis); - (negative): no clonal band on polyacrylamide gel electrophoresis and no dominant peak on fluorescence capillary electrophoresis; I: inadequate DNA quality for PCR
For clinical course: A: alive; D: death